Gabriele Fischer nominated again for Scientific Advisory Board of the EU Drugs Monitoring Centre

The EMCDDA (European Monitoring Centre for Drugs and Drug Addiction), based in Lisbon, was founded in 1993 with the aim of providing objective, reliable and comparable information that provides the Member States with an overview of the phenomenon of individual drugs and addictive diseases and their effects. To this end, a report on the state of the drug issues is published annually.

The Scientific Committee of EMCDDA consists of eleven renowned international scientists in the interdisciplinary field of substance use disorders. Its tasks include advising the agency on the management of the addiction and drug strategy for the European Union. In addition to the focus on "illicit substances", the mandate was recently expanded to include the areas of alcohol and behavioural addictions. "Our work is an important contribution to the political handling of the increasingly changing drug problem in the EU," says Gabriele Fischer.

About the person
Gabriele Fischer is a specialist in psychiatry and neurology and heads the Outpatient Drug Clinic at MedUni Vienna's Department of Psychiatry and Psychotherapy. An internationally renowned addiction expert, she also conducts research on a wide range of aspects of addictive disorders at MedUni Vienna's Centre for Public Health. She has also been an active human rights expert for many years and has extensive experience as a consultant to the UN and WHO. Nationally, among other things, she is a member of the Supreme Sanitary Council advising the Ministry of Health and, since 2016, on the international scientific committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Fischer has published more than 250 scientific papers and has given and continues to give numerous lectures on the subject of psychiatry, public health and the topic of human rights both nationally and internationally.